Document Detail

Formation of neutralizing antibodies after treatment with human calcitonin.
MedLine Citation:
PMID:  8213878     Owner:  NLM     Status:  MEDLINE    
PURPOSE: Calcitonin is used for the treatment of Paget's disease of bone, hypercalcemia, and postmenopausal osteoporosis. The formation of antibodies against heterologous calcitonins, such as salmon calcitonin (sCT), has been described frequently. Neutralizing effects of these antibodies have been demonstrated in many cases. As far as antibody formation against human calcitonin (hCT) is concerned, only a single case has been reported in the literature; however, investigations concerning the biologic activity of the antibodies were not performed. We have now assessed the sera of 33 patients treated with hCT for postmenopausal osteoporosis for a period of at least 12 months to evaluate the occurrence of hCT-binding and hCT-neutralizing antibodies. PATIENTS AND METHODS: Binding antibodies were detected by incubation of patient sera with 125I-labeled hCT; neutralizing activity was assessed in an in vitro bioassay that measured the impairment of the hCT-induced cyclic adenosine monophosphate (cAMP) formation in the human breast cancer cell line T47D. RESULTS: Prior to hCT treatment, none of the patients showed evidence of the presence of either binding or neutralizing antibodies. During the course of treatment, binding antibodies occurred in a single patient. These antibodies had a neutralizing activity characterized by 15% impairment of cAMP formation after 6 months and 27% impairment after 12 months of treatment compared with pretreatment control values. The neutralizing effect observed in this particular patient was comparatively mild compared with the effects seen after the formation of neutralizing antibodies against sCT, so major clinical sequelae were not expected in this patient. This may be due to the lower antigenicity of hCT as compared with sCT. CONCLUSION: Although antibody formation against hCT is a rare phenomenon, we nonetheless recommend monitoring of postmenopausal osteoporosis patients treated with sCT or hCT for neutralizing antibody formation in order to evaluate the therapeutic effect of treatment.
A Grauer; H H Reinel; S Lunghall; E Lindh; R Ziegler; F Raue
Related Documents :
25478018 - Identification of structural determinants on tau protein essential for its pathological...
25406488 - The association of serum anti-ribosomal p antibody with clinical and serological disord...
25306868 - Vimentin is a dominant target of in situ humoral immunity in human lupus tubulointersti...
24391138 - Interferon-gamma immunospot assay of pleural effusion mononuclear cells for diagnosis o...
2818968 - Histocompatibility antigens in a population based silicosis series.
1704188 - Immunoreactivity of anti-streptococcal monoclonal antibodies to human heart valves. evi...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The American journal of medicine     Volume:  95     ISSN:  0002-9343     ISO Abbreviation:  Am. J. Med.     Publication Date:  1993 Oct 
Date Detail:
Created Date:  1993-11-10     Completed Date:  1993-11-10     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0267200     Medline TA:  Am J Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  439-42     Citation Subset:  AIM; IM    
Department of Internal Medicine 1, Endocrinology and Metabolism, University of Heidelberg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antibody Formation / immunology
Biological Assay
Calcitonin / immunology*,  therapeutic use
Iodine Radioisotopes
Middle Aged
Neutralization Tests
Osteoporosis, Postmenopausal / drug therapy,  immunology
Reg. No./Substance:
0/Iodine Radioisotopes; 9007-12-9/Calcitonin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Verapamil intoxication: a literature review of overdoses and discussion of therapeutic options.
Next Document:  Human T lymphotropic virus type II (HTLV-II) infection among female prostitutes in Yucatan, Mexico.